Skip to content

Lobbying by Gilead Sciences Canada: its registrations, its lobbyists, the bills it has named and every meeting it has reported with federal office holders since November 2021.

← Lobbying

Corporation

Gilead Sciences Canada

Meetings this Parliament
47
With MPs
12
Since Nov 2021
107
Active registrations
1

Most recent reported meeting: Sep 22, 2026.

Who they meet

Since the current Parliament opened.

MPs

Institutions

  • Health Canada (HC)19
  • Innovation, Science and Economic Development Canada (ISED)16
  • House of Commons9
  • Treasury Board Of Canada Secretariat (TBS)6
  • Finance Canada (FIN)5
  • Senate of Canada4
  • Intergovernmental Affairs Secretariat (IGA)4
  • Public Health Agency of Canada (PHAC)3

Registrations in effect

In-house (corporation) In effect since Apr 2, 2026

Filed by Paul Petrelli, General Manager

Lobbyists

  • Bobby Sutherland · Sr. Director, Government Affairs
  • Paul Petrelli · General Manager

Institutions they may lobby: CUSMA Secretariat, Canadian Institutes of Health Research (CIHR), Correctional Service of Canada (CSC), Crown-Indigenous Relations and Northern Affairs Canada (CIRNAC), Finance Canada (FIN), Global Affairs Canada (GAC), Health Canada (HC), House of Commons, Immigration, Refugees and Citizenship Canada (IRCC), Indigenous Services Canada (ISC), Innovation, Science and Economic Development Canada (ISED), Intergovernmental Affairs Secretariat (IGA), Patented Medicine Prices Review Board (PMPRB), Prime Minister's Office (PMO), Privy Council Office (PCO), Public Health Agency of Canada (PHAC), Public Services and Procurement Canada (PSPC), Senate of Canada, Treasury Board Of Canada Secretariat (TBS)

What they're lobbying on (9)
  • Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations
  • Food and Drug regulations as it relates to data protection and the regulation and protection of biopharmaceutical products
  • Canada's Drug Agency (CDA) policies as it relates to health economics assessment and recommendations made on new medicines.
  • Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations.
  • Free Trade agreements as they relate to the biopharmaceutical industry
  • Policy and Programs Health Canada and Public Health Agency of Canada policies and programs to prevent and treat HIV and eliminate hepatitis as a public health threat by 2030, as part of Canada's commitments under the Global Viral Hepatitis Strategy and therapeutic efforts against the fight for COVID-19.
  • Patent Act Regulations as they relate to the regulation of intellectual property for therapeutic products, specifically the Patented Medicines (Notice of Compliance) Regulations Patented Medicine Prices Review Board (PMPRB) Regulations with regard to reporting requirements, pricing, guidelines and dispute resolution.
  • Innovation Agenda, particularly with respect to initiatives to support and attract investments in the life sciences sector
  • Federal Government First Nations and Inuit Health Branch program with respect to health services. Federally-funded Public Drug Plans, with respect to reimbursement for drug products for federal plan beneficiaries.

Registration 959600-360912-19. Look it up in the official Registry

Reported meetings

Spreadsheet

Filed by Paul Petrelli (50), Christophe Griolet (39), Scott Spencer (9), Melissa Koomey (9).

  • Reported by Paul Petrelli · In-house (corporation)

    • René Cormier · Senator, Senate of Canada
    Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations Read more

    Policy and Programs Health Canada and Public Health Agency of Canada policies and programs to prevent and treat HIV and eliminate hepatitis as a public health threat by 2030, as part of Canada's commitments under the Global Viral Hepatitis Strategy and therapeutic efforts against the fight for COVID-19.

    Free Trade agreements as they relate to the biopharmaceutical industry

    Official report

  • Reported by Paul Petrelli · In-house (corporation)

    Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations. Read more

    Innovation Agenda, particularly with respect to initiatives to support and attract investments in the life sciences sector

    Free Trade agreements as they relate to the biopharmaceutical industry

    Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations

    Official report

  • Reported by Paul Petrelli · In-house (corporation)

    Food and Drug regulations as it relates to data protection and the regulation and protection of biopharmaceutical products Read more

    Innovation Agenda, particularly with respect to initiatives to support and attract investments in the life sciences sector

    Free Trade agreements as they relate to the biopharmaceutical industry

    Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations.

    Policy and Programs Health Canada and Public Health Agency of Canada policies and programs to prevent and treat HIV and eliminate hepatitis as a public health threat by 2030, as part of Canada's commitments under the Global Viral Hepatitis Strategy and therapeutic efforts against the fight for COVID-19.

    Canada's Drug Agency (CDA) policies as it relates to health economics assessment and recommendations made on new medicines.

    Patent Act Regulations as they relate to the regulation of intellectual property for therapeutic products, specifically the Patented Medicines (Notice of Compliance) Regulations Patented Medicine Prices Review Board (PMPRB) Regulations with regard to reporting requirements, pricing, guidelines and dispute resolution.

    Official report

  • Reported by Paul Petrelli · In-house (corporation)

    • Pamela Aung-Thin · Assistant Deputy Minister, Health Canada (HC)
    • Sonia Corrent · Director General, Health Canada (HC)
    • Maria Sultan-Khan · Senior advisor, Health Canada (HC)
    Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations Read more

    Official report

  • Reported by Paul Petrelli · In-house (corporation)

    • Marjorie Michel · Minister of Health, Health Canada (HC)
    • Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
    • fatouma bah · Senior policy advisor, Innovation, Science and Economic Development Canada (ISED)
    • Kaili Levesque · Associate Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
    and 9 more
    • Nasser Haidar · Senior Policy Advisor, Intergovernmental Affairs Secretariat (IGA)
    • Elizabeth Wong · Senior Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
    • Annahat Kochhar · Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
    • Shalene Curtis-Micallef · Deputy Minister, Health Canada (HC)
    • Jocelyne Voisin · Senior Assistant Deputy Minister, Health Canada (HC)
    • Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
    • Justine Frame · Policy Advisor, Health Canada (HC)
    • Supriya Sharma · Acting Assistant Deputy Minister, Health Canada (HC)
    • Scott Lohnes · Senior advisor, Health Canada (HC)
    Innovation Agenda, particularly with respect to initiatives to support and attract investments in the life sciences sector Read more

    Free Trade agreements as they relate to the biopharmaceutical industry

    Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations.

    Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations

    Official report

  • Reported by Paul Petrelli · In-house (corporation)

    • Kaili Levesque · Associate Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
    • Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
    • Mackenzy Metcalfe · Policy Advisor, Finance Canada (FIN)
    • Elizabeth Wong · Senior Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
    and 6 more
    • Shalene Curtis-Micallef · Deputy Minister, Health Canada (HC)
    • Jocelyne Voisin · Senior Assistant Deputy Minister, Health Canada (HC)
    • Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
    • Justine Frame · Policy Advisor, Health Canada (HC)
    • Pamela Aung-Thin · Assistant Deputy Minister, Health Canada (HC)
    • Linsey Hollett · Assistant deputy Minister, Health Canada (HC)
    Free Trade agreements as they relate to the biopharmaceutical industry Read more

    Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations

    Innovation Agenda, particularly with respect to initiatives to support and attract investments in the life sciences sector

    Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations.

    Official report

  • Reported by Paul Petrelli · In-house (corporation)

    • Kaili Levesque · Associate Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
    • Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
    • Mackenzy Metcalfe · Policy Advisor, Finance Canada (FIN)
    • Shalene Curtis-Micallef · Deputy Minister, Health Canada (HC)
    and 6 more
    • Jocelyne Voisin · Senior Assistant Deputy Minister, Health Canada (HC)
    • Justine Frame · Policy Advisor, Health Canada (HC)
    • Jibril Hussein · Senior Policy Advisor, Health Canada (HC)
    • Pamela Aung-Thin · Assistant Deputy Minister, Health Canada (HC)
    • Linsey Hollett · Assistant deputy Minister, Health Canada (HC)
    • Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
    Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations Read more

    Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations.

    Official report

  • Reported by Paul Petrelli · In-house (corporation)

    • Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
    • Shalene Curtis-Micallef · Deputy Minister, Health Canada (HC)
    • Jocelyne Voisin · Senior Assistant Deputy Minister, Health Canada (HC)
    • Linsey Hollett · Assistant deputy Minister, Health Canada (HC)
    and 3 more
    • Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
    • Justine Frame · Policy Advisor, Health Canada (HC)
    • Pamela Aung-Thin · Assistant Deputy Minister, Health Canada (HC)
    Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations. Read more

    Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations

    Official report

  • Reported by Paul Petrelli · In-house (corporation)

    • Pamela Aung-Thin · Assistant Deputy Minister, Health Canada (HC)
    • Sara O'Connor · Associate Assistant Deputy Minister, Health Canada (HC)
    • Celia Lourenco · Associate Assistant Deputy Minister, Health Canada (HC)
    • Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
    and 6 more
    • Justine Frame · Policy Advisor, Health Canada (HC)
    • Sony Perron · Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
    • Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
    • Manuela Tomic · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
    • Elizabeth Wong · Senior Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
    • Annahat Kochhar · Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
    Innovation Agenda, particularly with respect to initiatives to support and attract investments in the life sciences sector Read more

    Food and Drug regulations as it relates to data protection and the regulation and protection of biopharmaceutical products

    Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations.

    Patent Act Regulations as they relate to the regulation of intellectual property for therapeutic products, specifically the Patented Medicines (Notice of Compliance) Regulations Patented Medicine Prices Review Board (PMPRB) Regulations with regard to reporting requirements, pricing, guidelines and dispute resolution.

    Canada's Drug Agency (CDA) policies as it relates to health economics assessment and recommendations made on new medicines.

    Official report

  • Reported by Paul Petrelli · In-house (corporation)

    • Maggie Chi · Member of Parliament
    • Shalene Curtis-Micallef · Deputy Minister, Health Canada (HC)
    • Jocelyne Voisin · Senior Assistant Deputy Minister, Health Canada (HC)
    • Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
    and 7 more
    • Justine Frame · Policy Advisor, Health Canada (HC)
    • Pamela Aung-Thin · Assistant Deputy Minister, Health Canada (HC)
    • Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
    • Elizabeth Wong · Senior Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
    • Annahat Kochhar · Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
    • Mackenzy Metcalfe · Policy Advisor, Finance Canada (FIN)
    • Nasser Haidar · Senior Policy Advisor, Intergovernmental Affairs Secretariat (IGA)
    Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations. Read more

    Canada's Drug Agency (CDA) policies as it relates to health economics assessment and recommendations made on new medicines.

    Innovation Agenda, particularly with respect to initiatives to support and attract investments in the life sciences sector

    Free Trade agreements as they relate to the biopharmaceutical industry

    Food and Drug regulations as it relates to data protection and the regulation and protection of biopharmaceutical products

    Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations

    Official report

  • Reported by Paul Petrelli · In-house (corporation)

    • Marjorie Michel · Minister of Health, Health Canada (HC)
    • Shalene Curtis-Micallef · Deputy Minister, Health Canada (HC)
    • Jocelyne Voisin · Senior Assistant Deputy Minister, Health Canada (HC)
    • Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
    and 6 more
    • Justine Frame · Policy Advisor, Health Canada (HC)
    • Linsey Hollett · Assistant deputy Minister, Health Canada (HC)
    • Sony Perron · Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
    • Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
    • Manuela Tomic · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
    • Rodrigo Arancibia · Director General, Innovation, Science and Economic Development Canada (ISED)
    Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations. Read more

    Innovation Agenda, particularly with respect to initiatives to support and attract investments in the life sciences sector

    Canada Agency for Drugs and Technologies in Health (CADTH) as it relates to health economics assessment and recommendations made on new medicines.

    Free Trade agreements as they relate to the biopharmaceutical industry

    Patent Act Regulations as they relate to the regulation of intellectual property for therapeutic products, specifically the Patented Medicines (Notice of Compliance) Regulations Patented Medicine Prices Review Board (PMPRB) Regulations with regard to reporting requirements, pricing, guidelines and dispute resolution.

    Official report

  • Reported by Paul Petrelli · In-house (corporation)

    • Philip Jennings · Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
    • Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
    Innovation Agenda, particularly with respect to initiatives to support and attract investments in the life sciences sector Read more

    Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations.

    Free Trade agreements as they relate to the biopharmaceutical industry

    Patent Act Regulations as they relate to the regulation of intellectual property for therapeutic products, specifically the Patented Medicines (Notice of Compliance) Regulations Patented Medicine Prices Review Board (PMPRB) Regulations with regard to reporting requirements, pricing, guidelines and dispute resolution.

    Canada Agency for Drugs and Technologies in Health (CADTH) as it relates to health economics assessment and recommendations made on new medicines.

    Official report

  • Reported by Paul Petrelli · In-house (corporation)

    • Jibril Hussein · Senior Policy Advisor, Health Canada (HC)
    • Justine Frame · Policy advisor, Health Canada (HC)
    Federal Government First Nations and Inuit Health Branch program with respect to health services. Federally-funded Public Drug Plans, with respect to reimbursement for drug products for federal plan beneficiaries. Read more

    Policy and Programs Health Canada and Public Health Agency of Canada policies and programs to prevent and treat HIV and eliminate hepatitis as a public health threat by 2030, as part of Canada's commitments under the Global Viral Hepatitis Strategy and therapeutic efforts against the fight for COVID-19.

    Official report

  • Reported by Paul Petrelli · In-house (corporation)

    • Justine Frame · Policy advisor, Health Canada (HC)
    Innovation Agenda, particularly with respect to initiatives to support and attract investments in the life sciences sector Read more

    Federal Government First Nations and Inuit Health Branch program with respect to health services. Federally-funded Public Drug Plans, with respect to reimbursement for drug products for federal plan beneficiaries.

    Patent Act Regulations as they relate to the regulation of intellectual property for therapeutic products, specifically the Patented Medicines (Notice of Compliance) Regulations Patented Medicine Prices Review Board (PMPRB) Regulations with regard to reporting requirements, pricing, guidelines and dispute resolution.

    Policy and Programs Health Canada and Public Health Agency of Canada policies and programs to prevent and treat HIV and eliminate hepatitis as a public health threat by 2030, as part of Canada's commitments under the Global Viral Hepatitis Strategy and therapeutic efforts against the fight for COVID-19.

    Canada Agency for Drugs and Technologies in Health (CADTH) as it relates to health economics assessment and recommendations made on new medicines.

    Official report

  • Reported by Paul Petrelli · In-house (corporation)

    • Dominic LeBlanc · President of the King's Privy Council for Canada and Minister of International Trade and Intergovernmental Affairs
    • Karim Bardeesy · Member of Parliament
    • Marjorie Michel · Minister of Health, Health Canada (HC)
    • Janice Charette · Chief Trade Negotiator to the United States, Privy Council Office (PCO)
    and 7 more
    • Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
    • Martin Moen · Associate Assistant Deputy Minister, Intergovernmental Affairs Secretariat (IGA)
    • Manuela Tomic · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
    • Nasser Haidar · Senior Policy Advisor, Intergovernmental Affairs Secretariat (IGA)
    • Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
    • Justine Frame · Special Assistant, Policy, Health Canada (HC)
    • Shalene Curtis-Micallef · Deputy Minister, Health Canada (HC)
    Innovation Agenda, particularly with respect to initiatives to support and attract investments in the life sciences sector Read more

    Free Trade agreements as they relate to the biopharmaceutical industry

    Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations.

    Official report

  • Reported by Paul Petrelli · In-house (corporation)

    • Pamela Aung-Thin · Assistant Deputy Minister, Health Canada (HC)
    Policy and Programs Health Canada and Public Health Agency of Canada policies and programs to prevent and treat HIV and eliminate hepatitis as a public health threat by 2030, as part of Canada's commitments under the Global Viral Hepatitis Strategy and therapeutic efforts against the fight for COVID-19. Read more

    Innovation Agenda, particularly with respect to initiatives to support and attract investments in the life sciences sector

    Patent Act Regulations as they relate to the regulation of intellectual property for therapeutic products, specifically the Patented Medicines (Notice of Compliance) Regulations Patented Medicine Prices Review Board (PMPRB) Regulations with regard to reporting requirements, pricing, guidelines and dispute resolution.

    Canada Agency for Drugs and Technologies in Health (CADTH) as it relates to health economics assessment and recommendations made on new medicines.

    Official report

  • Reported by Paul Petrelli · In-house (corporation)

    • Steven Sternthal · Director General, Public Health Agency of Canada (PHAC)
    • Semhar Zerat · Director, Public Health Agency of Canada (PHAC)
    • Fonju Ndemesah · Senior Policy Analyst, Public Health Agency of Canada (PHAC)
    • Tanya Lary · Director, Public Health Agency of Canada (PHAC)
    Federal Government First Nations and Inuit Health Branch program with respect to health services. Federally-funded Public Drug Plans, with respect to reimbursement for drug products for federal plan beneficiaries. Read more

    Policy and Programs Health Canada and Public Health Agency of Canada policies and programs to prevent and treat HIV and eliminate hepatitis as a public health threat by 2030, as part of Canada's commitments under the Global Viral Hepatitis Strategy and therapeutic efforts against the fight for COVID-19.

    Official report

  • Reported by Paul Petrelli · In-house (corporation)

    • Maggie Chi · Parliamentary Secretary, Health Canada (HC)
    • Justine Frame · Special Assistant, Policy, Health Canada (HC)
    • Nora Draper · Parliamentary Secretary Assistant, Health Canada (HC)
    Patent Act Regulations as they relate to the regulation of intellectual property for therapeutic products, specifically the Patented Medicines (Notice of Compliance) Regulations Patented Medicine Prices Review Board (PMPRB) Regulations with regard to reporting requirements, pricing, guidelines and dispute resolution. Read more

    Innovation Agenda, particularly with respect to initiatives to support and attract investments in the life sciences sector

    Canada Agency for Drugs and Technologies in Health (CADTH) as it relates to health economics assessment and recommendations made on new medicines.

    Official report

  • Reported by Paul Petrelli · In-house (corporation)

    • Annahat Kochhar · Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
    • Elizabeth Wong · Senior Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
    Innovation Agenda, particularly with respect to initiatives to support and attract investments in the life sciences sector Read more

    Patent Act Regulations as they relate to the regulation of intellectual property for therapeutic products, specifically the Patented Medicines (Notice of Compliance) Regulations Patented Medicine Prices Review Board (PMPRB) Regulations with regard to reporting requirements, pricing, guidelines and dispute resolution.

    Canada Agency for Drugs and Technologies in Health (CADTH) as it relates to health economics assessment and recommendations made on new medicines.

    Official report

  • Reported by Paul Petrelli · In-house (corporation)

    • Kyle Allen · Director of Communications, Crown-Indigenous Relations and Northern Affairs Canada (CIRNAC)
    Policy and Programs Health Canada and Public Health Agency of Canada policies and programs to prevent and treat HIV and eliminate hepatitis as a public health threat by 2030, as part of Canada's commitments under the Global Viral Hepatitis Strategy and therapeutic efforts against the fight for COVID-19. Read more

    Federal Government First Nations and Inuit Health Branch program with respect to health services. Federally-funded Public Drug Plans, with respect to reimbursement for drug products for federal plan beneficiaries.

    Official report

  • Reported by Paul Petrelli · In-house (corporation)

    • Justine Frame · Special Assistant, Policy, Health Canada (HC)
    Federal Government First Nations and Inuit Health Branch program with respect to health services. Federally-funded Public Drug Plans, with respect to reimbursement for drug products for federal plan beneficiaries. Read more

    Innovation Agenda, particularly with respect to initiatives to support and attract investments in the life sciences sector

    Policy and Programs Health Canada and Public Health Agency of Canada policies and programs to prevent and treat HIV and eliminate hepatitis as a public health threat by 2030, as part of Canada's commitments under the Global Viral Hepatitis Strategy and therapeutic efforts against the fight for COVID-19.

    Official report

  • Reported by Paul Petrelli · In-house (corporation)

    • Sandenga Yeba · Director of Policy and Deputy Chief of Staff, Health Canada (HC)
    • Justine Frame · Special Assistant, Policy, Health Canada (HC)
    Canada Agency for Drugs and Technologies in Health (CADTH) as it relates to health economics assessment and recommendations made on new medicines. Read more

    Innovation Agenda, particularly with respect to initiatives to support and attract investments in the life sciences sector

    Patent Act Regulations as they relate to the regulation of intellectual property for therapeutic products, specifically the Patented Medicines (Notice of Compliance) Regulations Patented Medicine Prices Review Board (PMPRB) Regulations with regard to reporting requirements, pricing, guidelines and dispute resolution.

    Federal Government First Nations and Inuit Health Branch program with respect to health services. Federally-funded Public Drug Plans, with respect to reimbursement for drug products for federal plan beneficiaries.

    Official report

  • Reported by Paul Petrelli · In-house (corporation)

    • Karim Bardeesy · Parliamentary Secretary, Innovation, Science and Economic Development Canada (ISED)
    • Chase Knight · Parliamentary Secretary Assistant, Innovation, Science and Economic Development Canada (ISED)
    • Lisa Xie · Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
    • Victoria Morton · Senior Communications Advisor, House of Commons
    Innovation Agenda, particularly with respect to initiatives to support and attract investments in the life sciences sector Read more

    Patent Act Regulations as they relate to the regulation of intellectual property for therapeutic products, specifically the Patented Medicines (Notice of Compliance) Regulations Patented Medicine Prices Review Board (PMPRB) Regulations with regard to reporting requirements, pricing, guidelines and dispute resolution.

    Canada Agency for Drugs and Technologies in Health (CADTH) as it relates to health economics assessment and recommendations made on new medicines.

    Official report

  • Reported by Paul Petrelli · In-house (corporation)

    • Annahat Kochhar · Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
    • Hosai Zurmati Halim · Senior Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
    • Elizabeth Wong · Senior Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
    Innovation Agenda, particularly with respect to initiatives to support and attract investments in the life sciences sector Read more

    Patent Act Regulations as they relate to the regulation of intellectual property for therapeutic products, specifically the Patented Medicines (Notice of Compliance) Regulations Patented Medicine Prices Review Board (PMPRB) Regulations with regard to reporting requirements, pricing, guidelines and dispute resolution.

    Canada Agency for Drugs and Technologies in Health (CADTH) as it relates to health economics assessment and recommendations made on new medicines.

    Official report

  • Reported by Paul Petrelli · In-house (corporation)

    • Greg Orencsak · Deputy Minister, Health Canada (HC)
    • Sarah Lawley · Assistant Deputy Minister, Health Canada (HC)
    • Pamela Aung-Thin · Assistant Deputy Minister, Health Canada (HC)
    Innovation Agenda, particularly with respect to initiatives to support and attract investments in the life sciences sector Read more

    Patent Act Regulations as they relate to the regulation of intellectual property for therapeutic products, specifically the Patented Medicines (Notice of Compliance) Regulations Patented Medicine Prices Review Board (PMPRB) Regulations with regard to reporting requirements, pricing, guidelines and dispute resolution.

    Official report

From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.